ReviewDiscover nano2026
A deep dive into ferritin nanoparticle advancements: experimental and computational perspectives.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferritin, a natural iron-storage protein, has emerged as a versatile platform in nanotechnology and biomedicine due to its biocompatible 12 nm nanocage, intrinsic targeting via the transferrin receptor 1, and adaptability for diverse applications. This review integrates recent experimental and computational advances in ferritin-based nanoparticles, Ferritin is used for drug delivery, vaccine delivery, gene therapy, imaging and diagnostics, antioxidant therapy, and anti-inflammatory and neuroprotective therapies. Experimentally, ferritin nanocages achieve high-capacity loading (up to 400 molecules per cage) of therapeutics such as doxorubicin, siRNA, and CRISPR-Cas9 through pH-responsive disassembly, passive diffusion, and engineered self-assembly. Its natural TfR1 affinity enables precise tumor targeting and blood-brain barrier penetration, improving outcomes in cancers, infectious diseases, and neurological disorders. Computationally, molecular dynamics simulations predict stable antigen-ferritin interfaces. Density functional theory elucidates metal-oxide interactions in catalytic nanozymes. Machine learning classifiers leverage ferritin biomarkers for iron deficiency anemia detection, and bioinformatics tools like weighted gene co-expression network analysis and protein-protein interaction networks reveal ferritinophagy mechanisms in neurodegeneration and cancer. Docking-guided designs enhance vaccine epitope exposure and PROTAC degradation efficiency, fostering precision diagnostics and sustainable nanocarrier optimization. Despite promising preclinical results, challenges in scalability, long-term immunogenicity, and regulatory validation persist. This review highlights ferritin's revolutionary potential in nanomedicine, proposing future directions for AI-assisted design, personalized therapies, and sustainable nanotechnology to overcome barriers for clinical use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.